Intraoperative AnalgesiaNOLGADELSNCT06104059
NOL Guided Analgesia During Elective Laparoscopic Surgery Under General Anesthesia
A study testing Nociception level index (NOL™) and Fentanyl in people with Intraoperative Analgesia, run by Attikon Hospital at 1 site in Greece.
Trial summary
The aim of this study is to investigate the hypothesis that the intraoperative use of the nociception level index NOL can reduce opioid consumption in adult patients undergoing elective laparoscopic surgeries under general anesthesia, as well as to explore its effect on post-operative pain and patient recovery. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Intraoperative Analgesia
- What is being tested?
- Nociception level index (NOL™) and Fentanyl
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteGreece
- Study dates
- 20 Apr 2023to 20 Sep 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients undergoing planned laparoscopic surgery under general anesthesia.
Who cannot join
- Emergency surgery.
- Pregnancy.
- Drug or alcohol abuse in the last 6 months.
- Chronic opioid use or patients with chronic pain.
- Serious comorbidity [cardiac disease (atrial fibrillation, ventricular arrhythmias), liver or kidney disease]
- Obesity (BMI >35).
Show all 10Show fewer
- Permanently implanted pacemaker.
- Patients with CNS disease.
- Allergy to any of the study drugs.
- Patients receiving anticholinergics agonists, α2-adrenergic agonists, β1-adrenergic antagonists, antiarrhythmic drugs.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Greece1 site, 1 recruiting
- Recruiting
2nd Department of Anesthesiology, Attikon University Hospital
Athens, Attica, 12462
Paraskevi Matsota, Prof
Paraskevi Mastota, MD, PhD
About this study
Official title: Ιntraoperative Administration of Opioids Guided by the Nociception Level Index NOL in Elective Laparoscopic Surgeries Under General Anesthesia: Effect on Opioid Consumption, Post-operative Pain and Patient Recovery
The aim of this study is to investigate the hypothesis that the intraoperative use of the nociception level index NOL can reduce opioid consumption in adult patients undergoing elective laparoscopic surgeries under general anesthesia, as well as to explore its effect on post-operative pain and patient recovery.
Read the detailed description
The study is a Prospective Randomized clinical trial. Adult patients (>18y) undergoing elective laparoscopic surgery under general anesthesia will be included.
The patients will be randomized using the "sealed envelope" randomization method into two groups.
Intervention group: in this group, the nociception level index NOL will be used in order to guide intraoperative analgesia. Control group: in this group standard anesthetic care will be provided. Analgesic demands will be treated with bolus doses of iv fentanyl.
All patients will receive the same general anesthesia induction regimen. Patients upon entering the operating room will have standard monitoring applied [Noninvasive Blood Pressure (NIBP), ECG, SpO2] and a venous line placed. The depth of anesthesia will also be monitored by using the BIS sensor and placement of the NOL sensor. Specifically, a sensor (Covidien, BIS™ monitoring system with 3.50 software) will be placed on the forehead (after cleaning with an rubbing alcohol solution) and an NOL sensor (Medasense Biometrics Ltd., PMD200™) on a finger on the opposite upper extremity to that on which the blood pressure cuff will beplaced. Neuromuscular blockade will also be monitored using a neurostimulator (Organon, TOF-Watch SX) to stimulate and record the response of the ulnar nerve to TOF. Before induction to general anesthesia, all patients receive an IV bolus 1mg of midazolam and preoxygenation is performed for 5 minutes with a mask (FiO2: 100%, FGF: 12 l/min). Induction to general anesthesia will be performed with propofol 2.5mg/kg iv and fentanyl 2mcg/kg iv and once a BIS <60 is achieved, rocuronium 0.6mg/kg iv will be administered. At the same time, the patient's ventilation is supported with a mask and bag (FiO2:100%). When TOF=0, endotracheal intubation will be performed. After intubation, maintenance of anesthesia will be achieved by administration of sevoflurane 0.7 MAC in 50% O2/Air and co-administration of iv propofol infusion (75-150mcg/kg/min) with target BIS: 40-60. Subsequently, 8 mg iv dexamethasone and 0.1 mg/kg iv morphine will be administered and an arterial catheter is placed for continuous blood pressure measurement. Before the surgical incision, fentanyl IV 1.5mcg/kg will be administered and the surgical incisions will be infiltrated with a 0.375% ropivacaine solution of 20ml. Intraoperatively, to achieve optimal analgesia, iv fentanyl will be administered according to the group to which the patient has been allocated, as described above. Half an hour before the end of the operation, 1g paracetamol iv and 4mg ondasetron iv will be administered and 20 minutes before the end of the surgical procedure, the propofol infusion will stop.
Reversal of peripheral neuromuscular blockade will be perfomed using sugammadex: 2-4mg/kg, depending on the indication of the neurostimulator. The patient will be extubated if TOF=4 \& TOF ratio ≥0.9 and BIS >80. Subsequently, the patient will be transferred to the Post Anesthesia Care Unit (PACU).
In PACU, intensity of postoperative pain will be assessed every 15 minutes with the Visual analogue scale (VAS, 0-10) and for a score >4, morphine 1mg iv bolus will be administered (up to 0.15mg/kg morphine in total for each patient including the intraoperative dose) until the patient is released from PACU.
Patient recovery will be assessed using the Post Anesthesia Recovery Score (PAR-Score), i.e. the Modified Aldrete score initially as soon as the patient is transferred to the PACU and patients will be released from PACU once they have score ≥9. The length of stay in the PACU until a score ≥9 is reached will also be recorded.
Any events or adverse effects (respiratory depression, lethargy, nausea, vomiting, itching, etc.) will also be recorded in the PACU.
- Conditions
- Intraoperative Analgesia
- Being tested
- Nociception level index (NOL™), Fentanyl
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nociception level index (NOL™)Device
If a NOL value >25 persists for >1 minute a bolus of iv fentanyl 0.5mcg/kg will be given and reassessment of the NOL value will continue every 5 minutes. If NOL index value: 10-25 is not reached within 10 minutes, fentanyl 0.5mcg/kg iv is re-administered.
FentanylOther
Bolus doses of iv fentanyl 0.5 mcg/kg will be administered based on the judgment of the anesthesiologist in charge.
| Study group | Role | What they receive |
|---|---|---|
| Nociception level index (NOL™) | Active comparator | The nociception level index NOL will be used in order to quide intraopertaive analgesia. Receives: Device: Nociception level index (NOL™) |
| Standard of care | Active comparator | Intraoperative analgesia will be based on common practice, i.e. changes in hemodynamic parameters. Receives: Other: Fentanyl |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intraoperative total consumption of opioids
Intraoperative total consumption of opioids will be calculated in all patients.
Measured: Up to 30 minutes after the end of operation
Secondary outcomes (2)
Postoperative administration of opioids in PACU
Total consumption of opioids will be calculated in all patients
Measured: Until the patient is released from PACU (up to 24 hours)
Intensity of postoperative pain in PACU
In PACU, intensity of postoperative pain will be assessed every 15 minutes with the Visual analogue scale, a 10 points scale (0= no pain and 10= worst pain)
Measured: Until the patient is released from PACU (up to 24 hours)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Oct 2023
- Study start20 Apr 2023
- Primary completion20 Sep 2027 (estimated)
- Study completion20 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intraoperative AnalgesiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, Randomized clinical trial
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Attikon Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Paraskevi Matsota, Attikon Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06104059
- Sponsor's protocol ID
- NOLGADELS
- Acronym
- NOLGADELS
- Status last verified
- Mar 2026
- First submitted
- 22 Oct 2023
- Last updated
- 30 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ιntraoperative Administration of Opioids Guided by the Nociception Level Index NOL in Elective Laparoscopic Surgeries Under General Anesthesia: Effect on Opioid Consumption, Post-operative Pain and Patient Recovery
- ClinicalTrials.gov ID
- NCT06104059
- Acronym / sponsor ID
- NOLGADELS / NOLGADELS
- Conditions
- Intraoperative Analgesia
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Attikon HospitalUniversity, hospital or other
- Study start
- 20 Apr 2023 (actual)
- Primary completion
- 20 Sep 2027 (estimated)
- Study completion
- 20 Sep 2028 (estimated)
- First posted
- 27 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to investigate the hypothesis that the intraoperative use of the nociception level index NOL can reduce opioid consumption in adult patients undergoing elective laparoscopic surgeries under general anesthesia, as well as to explore its effect on post-operative pain and patient recovery.
Detailed description
The study is a Prospective Randomized clinical trial. Adult patients (>18y) undergoing elective laparoscopic surgery under general anesthesia will be included.
The patients will be randomized using the "sealed envelope" randomization method into two groups.
Intervention group: in this group, the nociception level index NOL will be used in order to guide intraoperative analgesia. Control group: in this group standard anesthetic care will be provided. Analgesic demands will be treated with bolus doses of iv fentanyl.
All patients will receive the same general anesthesia induction regimen. Patients upon entering the operating room will have standard monitoring applied [Noninvasive Blood Pressure (NIBP), ECG, SpO2] and a venous line placed. The depth of anesthesia will also be monitored by using the BIS sensor and placement of the NOL sensor. Specifically, a sensor (Covidien, BIS™ monitoring system with 3.50 software) will be placed on the forehead (after cleaning with an rubbing alcohol solution) and an NOL sensor (Medasense Biometrics Ltd., PMD200™) on a finger on the opposite upper extremity to that on which the blood pressure cuff will beplaced. Neuromuscular blockade will also be monitored using a neurostimulator (Organon, TOF-Watch SX) to stimulate and record the response of the ulnar nerve to TOF. Before induction to general anesthesia, all patients receive an IV bolus 1mg of midazolam and preoxygenation is performed for 5 minutes with a mask (FiO2: 100%, FGF: 12 l/min). Induction to general anesthesia will be performed with propofol 2.5mg/kg iv and fentanyl 2mcg/kg iv and once a BIS <60 is achieved, rocuronium 0.6mg/kg iv will be administered. At the same time, the patient's ventilation is supported with a mask and bag (FiO2:100%). When TOF=0, endotracheal intubation will be performed. After intubation, maintenance of anesthesia will be achieved by administration of sevoflurane 0.7 MAC in 50% O2/Air and co-administration of iv propofol infusion (75-150mcg/kg/min) with target BIS: 40-60. Subsequently, 8 mg iv dexamethasone and 0.1 mg/kg iv morphine will be administered and an arterial catheter is placed for continuous blood pressure measurement. Before the surgical incision, fentanyl IV 1.5mcg/kg will be administered and the surgical incisions will be infiltrated with a 0.375% ropivacaine solution of 20ml. Intraoperatively, to achieve optimal analgesia, iv fentanyl will be administered according to the group to which the patient has been allocated, as described above. Half an hour before the end of the operation, 1g paracetamol iv and 4mg ondasetron iv will be administered and 20 minutes before the end of the surgical procedure, the propofol infusion will stop.
Reversal of peripheral neuromuscular blockade will be perfomed using sugammadex: 2-4mg/kg, depending on the indication of the neurostimulator. The patient will be extubated if TOF=4 \& TOF ratio ≥0.9 and BIS >80. Subsequently, the patient will be transferred to the Post Anesthesia Care Unit (PACU).
In PACU, intensity of postoperative pain will be assessed every 15 minutes with the Visual analogue scale (VAS, 0-10) and for a score >4, morphine 1mg iv bolus will be administered (up to 0.15mg/kg morphine in total for each patient including the intraoperative dose) until the patient is released from PACU.
Patient recovery will be assessed using the Post Anesthesia Recovery Score (PAR-Score), i.e. the Modified Aldrete score initially as soon as the patient is transferred to the PACU and patients will be released from PACU once they have score ≥9. The length of stay in the PACU until a score ≥9 is reached will also be recorded.
Any events or adverse effects (respiratory depression, lethargy, nausea, vomiting, itching, etc.) will also be recorded in the PACU.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Prospective, Randomized clinical trial
| Arm | Type | Receives |
|---|---|---|
| Nociception level index (NOL™) | Active comparator | Device: Nociception level index (NOL™)The nociception level index NOL will be used in order to quide intraopertaive analgesia. |
| Standard of care | Active comparator | Other: FentanylIntraoperative analgesia will be based on common practice, i.e. changes in hemodynamic parameters. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Adult patients undergoing planned laparoscopic surgery under general anesthesia.
Key exclusion criteria (10 listed)
- Emergency surgery.
- Pregnancy.
- Drug or alcohol abuse in the last 6 months.
- Chronic opioid use or patients with chronic pain.
- Serious comorbidity [cardiac disease (atrial fibrillation, ventricular arrhythmias), liver or kidney disease]
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nociception level index (NOL™)If a NOL value >25 persists for >1 minute a bolus of iv fentanyl 0.5mcg/kg will be given and reassessment of the NOL value will continue every 5 minutes. If NOL index value: 10-25 is not reached within 10 minutes, fentanyl 0.5mcg/kg iv is re-administered. | Device | Nociception level index (NOL™) |
| FentanylBolus doses of iv fentanyl 0.5 mcg/kg will be administered based on the judgment of the anesthesiologist in charge. | Other | Standard of care |
Primary outcome
Intraoperative total consumption of opioids
Time frame: Up to 30 minutes after the end of operation
Intraoperative total consumption of opioids will be calculated in all patients.
2 secondary outcomes
Postoperative administration of opioids in PACU
Time frame: Until the patient is released from PACU (up to 24 hours)
Intensity of postoperative pain in PACU
Time frame: Until the patient is released from PACU (up to 24 hours)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Intraoperative Analgesia
Recruiting
Anterior Nerves of the Knee Block Versus Femoral Nerve Block for Knee Arthroscopy
Postoperative Pain, Knee Arthroscopy
RecruitingPhase 4
Perioperative Rectal Methadone in Spine Surgery
Spinal Surgery, Post-operative Care
Not yet recruitingObservational study
Evaluation of Consciousness Depth (qCON) and Analgesia Depth (qNOX) Indices in General Anesthesia
Cesarean Section (MeSH: D002585), Anesthesia
RecruitingPhase 4
Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck Cancers
Head and Neck Carcinoma, Hypopharyngeal Carcinoma
Recruiting
Effect of Scalp Block on Intraoperative Hemodynamics and Postoperative Pain in Craniotomy Patients"
Scalp Block
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nociception level index (NOL™) and Fentanyl in people with Intraoperative Analgesia, run by Attikon Hospital at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact PARASKEVI Prof MATSOTA (6945544563, matsota@yahoo.gr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intraoperative total consumption of opioids (time frame: Up to 30 minutes after the end of operation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.